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Abstract
Introduction: Vasospastic brain infarction is a devastating complication of aneurysmal subarachnoid hemorrhage (SAH).
Using a probe for invasive monitoring of brain tissue oxygenation or blood flow is highly focal and may miss the site of
cerebral vasospasm (CVS). Probe placement is based on the assumption that the spasm will occur either at the dependent
vessel territory of the parent artery of the ruptured aneurysm or at the artery exposed to the focal thick blood clot. We
investigated the likelihood of a focal monitoring sensor being placed in vasospasm or infarction territory on a hypothetical
basis.
Methods: From our database we retrospectively selected consecutive SAH patients with angiographically proven (day 7–14)
severe CVS (narrowing of vessel lumen .50%). Depending on the aneurysm location we applied a standard protocol of
probe placement to detect the most probable site of severe CVS or infarction. We analyzed whether the placement was
congruent with existing CVS/infarction.
Results: We analyzed 100 patients after SAH caused by aneurysms located in the following locations: MCA (n = 14), ICA
(n = 30), A1CA (n = 4), AcoA or A2CA (n = 33), and VBA (n = 19). Sensor location corresponded with CVS territory in 93% of
MCA, 87% of ICA, 76% of AcoA or A2CA, but only 50% of A1CA and 42% of VBA aneurysms. The focal probe was located
inside the infarction territory in 95% of ICA, 89% of MCA, 78% of ACoA or A2CA, 50% of A1CA and 23% of VBA aneurysms.
Conclusion: The probability that a single focal probe will be situated in the territory of severe CVS and infarction varies. It
seems to be reasonably accurate for MCA and ICA aneurysms, but not for ACA or VBA aneurysms.
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Introduction
The occurrence of symptomatic vasospasm in patients with
aneurysmal subarachnoid hemorrhage (SAH) is a major complica-
tion [1]. Approximately 70% of patients develop an angiographic
cerebral vasospasm (CVS) between days 3 and 14 after SAH [2].
Neurological deficits due to delayed cerebral ischemia or infarction
occur in 20–40% of patients [1,3–5]. The most potent risk factor for
the development of CVS is the presence of thick clots in the basal
cisterns [6]. Additional risk factors for development of a cerebral
ischemia due to vasospasm are a poor clinical grade [7], acute and
chronic hypertension [7], fever [7], intravascular volume depletion
[8] and cigarette smoking [9]. Although pharmacological and
hemodynamic rescue therapies are feasible [10,11], often the timing
of more aggressive treatments is problematic. Microdialysis, mea-
surement of focal cerebral blood flow (CBF) or intraparenchymal
tissue oxygen tension (ptiO2) are potentially sensitive and continuous
techniques that could be used for diagnosis and treatment of
hemodynamic consequences of CVS [12,13]. Thesemeasurements,
however,arehighly focalandaremostcommonlybeneficialwhenthe
site of sensor placement corresponds to the territory of the arterywith
the maximum vasospasm.
The widespread clinical assumption is that the maximum of CVS
occurs at the vessel in contact with the largest clot that usually
corresponds to the vessel harboring the ruptured aneurysm.
However, data describing this correlation in the literature is limited
[14,15,16] and therefore the rates of missing severe CVS or
infarctions by monitoring with a focal sensor are unknown. The
main issue of this study was to approve the generally accepted
algorithm for choosing the side and site to place a focal sensor
according to the vessel of aneurysmrupture basedonour collective of
SAH patients with angiographically severe CVS. We sought to
quantify the likelihoodthata focallyplacedprobewouldbesituated in
the territory where severe CVS or infarction occurs.
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Methods
Database and Inclusion Criteria
Data for the study were collected from two similar databases
established in both participating departments (Goethe University
Hospital, Frankfurt/Main, Germany and Inselspital University
Hospital, Bern, Switzerland). 100 consecutive patients with
angiographically proven ruptured intradural aneurysms catego-
rized as World Federation of Neurological Surgeons (WFNS)
grade I to V and Fisher grade 3, and severe CVS between day 7
and 14 after hemorrhage were retrospectively selected. The CVS
occurred in at least one major vessel territory (internal carotid
artery [ICA], middle cerebral artery [MCA] M1, M2, anterior
cerebral artery [ACA] A1, A2, or vertebrobasilary arteries [VBA]).
CVS was regarded as severe when the narrowing of the arterial
vessel lumen exceeded 50% of the normal caliber based on digital
subtraction angiography (DSA) measurements.
The clinical diagnosis of CVS was made in patients who were
suitable for neurological examination and had a newly diagnosed
neurological deficit after exclusion of all other potential causes of
neurological deterioration or a drop in Glasgow Coma Scale
(GCS) of at least two points. Analgosedated and ventilated patients
were monitored daily by transcranial Doppler sonography (TCD).
Clinical signs of CVS or monitoring parameters triggered an
angiography or stroke magnetic resonance imaging (MRI). In
patients without clinical signs, these were performed routinely on
day 7 after bleeding. All patients were treated according to
a standardized protocol that has been described elsewhere [17].
Patient data was only available to the study leaders, and was
anonymized for all others and for the current study. The study was
registered with the ethics committees responsible for both
university hospitals. There was no individual written patient
consent because patients in the acute phase of SAH are often
lethargic, confused, or in a coma. In general, a retroactive consent
for analysis of data for patients with severe SAH is extremely
difficult due to their generally poor condition, and the number of
patients available to give retroactive consent is extremely limited.
Protocol of Probe Placement and Analyses of
Angiographic CVS
Sideandsite for sensorplacementwasdeterminedusingastandard
algorithm according to the location of the aneurysm. Probe
placement was as follows (see Table 1): for anterior cerebral artery
(ACA) A1 segment (A1CA) aneurysms, the ipsilateral ACA territory
was selected, and for anterior communicating artery (ACoA) or
anterior cerebral artery A2 segment (A2CA) aneurysms, the right
ACA territory was selected. For middle cerebral artery (MCA) and
ICA aneurysms, the ipsilateral MCA territory was selected, and for
VBA aneurysms, the right MCA territory was selected.
In the MCA territory, the sensor was inserted 10 mm in front of
the coronary suture and 60 mm paramedian. For the ACA
territory, the sensor was inserted 10 mm in front of the coronary
suture and 20 mm paramedian. In both locations, the probe was
placed subcortically at a depth of 20–30 mm below the dura mater
level through a burr hole.
To determine whether severe CVS occurs in the vessel territory
of ruptured aneurysm, 100 angiographies were analyzed. The
presence of severe CVS was matched with the probe placement
according to the described protocol. Therefore, our analytic
procedure was purely theoretical.
Regardless of those conditions, the analysis of hypothetical probe
placement in correlation to the site and side of severe CVS in the
angiography was the same in patients with or without a cerebral
probe. The cerebral probes were implanted in patients who were
either inpoorclinical condition (WFNSgradeIVorV) thatprevented
neurological assessment (e.g., due to analgosedation and ventilation)
with signs of CVS, or were in primarily good condition (WFNS I-III)
with neurological deterioration due to CVS.
Data Analyses
Data were recorded with IBM SPSS Statistics 12.0 (SPSS Inc.,
Chicago, IL). Descriptive statistics were used for analysis of the
findings. The relation between aneurysm location and CVS, as
well as between the CVS and cerebral infarction occurrence is
given as percentage (%) in Figures 1 and 2.
We also analyzed the likelihood that the probe location as
chosen by the described protocol corresponded to the territory of
the vessels with severe angiographic vasospasm and/or infarction
as documented in our database.
Results
All patients included in this study were selected from the
database because they had severe angiographic CVS (.day 6) of
.50% arterial narrowing compared to the admission angiogram.
We analyzed 14 MCA, 30 ICA, 33 AcoA or A2CA, 4 A1CA, and
19 VBA aneurysms. The median age was 47.7 years (range from
17 to 77 years). The male to female ratio was 1:1.5. Clipping (65
patients) or coil embolization (35 patients) was performed within
72 hours of hemorrhage. Regardless of the angiographic analyses
of severe CVS, 19 patients had an invasive cerebral probe (LicoxH,
Integra). The remaining 81 patients had no cerebral probe
monitoring.
Estimation of the Likelihood of Probe Placement in the
Vessel Territory of Severe CVS
Severe CVS corresponded to the probe’s position (ipsilateral
MCA territory) in 93% (n= 13) of MCA aneurysms, and in 87%
(n= 26) of ICA aneurysms (Figure 1 and Table 2). The ipsilateral
A1CA showed severe CVS in the probe area in 50% of A1CA
aneurysms (n= 2). In AcoA and A2CA aneurysms where the
probe was placed into the right ACA territory, CVS occurred in
Table 1. Clinical algorithm used to guide placement of sensor relative to the location of the aneurysm.
Vessel territory of probe placement Aneurysm bearing vessel
MCA right MCA right, ICA right, posterior circulation
MCA left MCA left, ICA left
ACA right ACA right, AcoA
ACA left ACA left
MCA=middle cerebral artery; ICA = internal carotid artery; ACA= anterior cerebral artery.
doi:10.1371/journal.pone.0062754.t001
Probe Location and Occurrence of CVS
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the probe’s territory in 76% (n= 25). In VBA aneurysms, severe
vasospasm occurred only in 42% (n= 8) in the right MCA territory
where the sensor was placed according to the protocol. Further-
more, severe CVS occurred outside the vessel territory of the
probe in 7% of MCA aneurysms, 13% of ICA aneurysms, 24% of
AcoA and A2CA aneurysms, 50% of A1CA aneurysms and 58%
of VBA aneurysms (Figure 1 and Table 2).
We also analyzed whether a modified sensor placement
algorithm might result in an improvement of sensitivity, but all
other schemes resulted in a lower rate of diagnosing severe CVS.
Frequency of Probe Location within the Territory of
Vasospastic Infarction
As the main selection criteria for this investigation was acutely
ruptured aneurysm and angiographically severe delayed vaso-
spasm (.50% arterial narrowing), we also analyzed the correlation
between the position of the probe and the likelihood of monitoring
in a territory where vasospastic infarction occurs (Figure 2). In
patients with ruptured MCA aneurysms (n = 14), infarction
occurred in 64% of cases (n = 9). In 89% (n= 8) of patients with
ruptured aneurysm and infarction, the infarction occurred in the
probe’s location, i.e. the MCA territory ipsilateral to the MCA
aneurysm. In one patient there was an infarction on the
contralateral side and 5 patients had no infarctions. Of the
patients with ICA aneurysms (n = 30), infarction occurred in 63%
(n= 19). In 95% (18 out of 19 patients), infarction occurred
ipsilaterally, i.e. within the probe’s location. Only one infarction
occurred contralaterally and 11 patients had no infarction. Of the
A1CA aneurysms (n= 4), infarction occurred in all 4 patients. In
50% of the cases, infarction occurred in the probe’s territory and
50% occurred outside the probe’s territory. Of the patients with
AcoA or A2CA aneurysms (n= 33), infarction occurred in 55% of
cases (n = 18). In 14 out of 18 patients, infarction occurred within
the probe’s location and in 22% outside the probe’s location.
Fifteen patients with AcoA or A2CA aneurysms had no infarction
(46%). In patients with posterior circulation (VBA) aneurysms
(n= 19), cerebral infarction occurred in 68% (n= 13). Of those,
23% of infarctions occurred within the territory of the probe (right
MCA territory) and 77% outside the probe’s territory. In 6
patients with VBA aneurysms no infarction occurred (32%).
Discussion
Monitoring focal cerebral blood flow or metabolic or tissue
oxygen changes in an area that is considered at risk for ischemic
injury after SAH may have an impact on treatment of CVS. The
problem of highly focal measurements with these probes is well-
known, but the numbers supporting this problem are limited
[14,15,16]. Different methods of positioning a catheter into the
vascular territory deemed at highest risk for developing CVS and
hypoperfusion have been previously reported [12,13,18]. One
study estimated about a 20% risk to misplace the probe and miss
the area of hypoperfusion [12]. The insertion of two catheters for
MCA and ICA aneurysms into the ipsilateral MCA and ACA
territories, and ACoA aneurysms bilateral into the ACA area [13]
was also described. However, these data indicated only a minor
benefit for multiple probes compared with a proper unifocal
monitoring approach [13].
Figure 1. Percentage of patients, by aneurysm type, with corresponding position of probe in relation to CVS.
doi:10.1371/journal.pone.0062754.g001
Probe Location and Occurrence of CVS
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According to the Consensus Meeting on Microdialysis in
Neurointensive care, the positioning of catheters should be
directed towards the tissue at risk, most likely the parent vessel
territory [19]. However, the reliability of this procedure has not
been evaluated. Sarrafzadeh et al. [18] proposed that the tissue at
risk is most likely the parent vessel territory of the aneurysm.
Recent investigations also have found a correlation between the
distribution of CVS and ruptured aneurysm site [7,20–22].
Harrod et al. [23] reviewed risk factors for CVS and found
inconclusive circumstances for a correlation between ruptured
aneurysm location and incidence of CVS, which would limit the
value of focal measurements. The classical study by Fisher et al.
[6] described the relation between a focal collection of blood as
a risk factor for nearby CVS. Conversely, Graf and Nibbelink [24]
found that 50% of patients with an ICA aneurysm, 45% of
patients with a MCA aneurysm, and 35% of patients with an ACA
aneurysm had localized or diffuse vasospasm. Furthermore, other
studies have shown that the incidence of vasospasm is higher in
patients with aneurysms of the medial circle of Willis, such as those
of ICA, compared to patients with aneurysms located more
Figure 2. Percentage of patients, by aneurysm type, with probe in the territory of vessel infarction.
doi:10.1371/journal.pone.0062754.g002
Table 2. Number of patients according to aneurysm type, location of the probe and occurrence of infarction.
Aneurysm location Total aneurysms CVS in probe area
CVS outside probe
area
Infarct inside
probe territory
Infarct outside
probe territory No infarct
MCA right 6 6 0 3 0 3
MCA left 8 7 1 5 1 2
ICA right 15 12 3 10 1 4
ICA left 15 14 1 8 0 7
A1CA right 3 1 2 1 2 0
A1CA left 1 1 0 1 0 0
AcoA, A2CA 33 25 8 14 4 15
VBA 19 8 11 3 10 6
MCA=middle cerebral artery; ICA = internal carotid artery; ACA= anterior cerebral artery; ACA= anterior cerebral artery; A1CA= anterior cerebral artery A1 segment,
A2CA= anterior cerebral artery A2 segment: VBA= vertebrobasilary arteries.
doi:10.1371/journal.pone.0062754.t002
Probe Location and Occurrence of CVS
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peripherally [25,26]. McGirt et al. [27] found that patients with
ruptured posterior cerebral artery (PCA) aneurysms were 20-times
less likely to develop symptomatic vasospasm. In contrast, other
reports suggest that the frequency of vasospasm does not vary with
anatomic position [28,29]. For example, in a study of 100
consecutive patients with aneurysmal SAH, Bonilha et al.
demonstrated no difference in the incidence of vasospasm as
a function of aneurysm size or location [30]. Despite these
findings, focal measurements are accepted as part of the clinical
management in patients after SAH, especially to guide therapy
when vasospastic hypoperfusion occurs. We therefore sought to
quantify the risk of missing a severe vasospasm or infarction when
using an accepted clinical algorithm to determine where to
implant a focal sensor depending on the aneurysm location.
Although cerebral ischemia after SAH also occurs without
angiographically visible CVS of a large proximal artery [31–33],
we found it necessary to select the patients for our study based on
a morphological correlate.
For different aneurysm sites, we found different likelihoods of
capturing severe CVS by a focal sensor. It was highest in MCA
and ICA aneurysms, with a chance of 87–93% of a successful
monitoring approach. In AcoA and A2CA aneurysms, the rate of
successful monitoring was 76%, whereas in A1CA and VBA the
rate was as low as 50% and 42% respectively, although this may
be explained in part by the low number of A1CA cases.
Aneurysms of the posterior circulation were monitored by placing
a probe into the right MCA territory, which was in fact distant
from the ruptured aneurysm. However, placement of a probe
directly into the territory of the posterior circulation is not a routine
clinical approach and appears to be more dangerous. On the other
hand, also in VBA aneurysms, the thick diffuse or localized clot is
also most often found around the circle of Willis.
According to the literature [1,3,5,22,33–35], vasospastic in-
farction may occur in up to 40% of patients or even up to 60%
when MRI studies are used. In our study, the numbers of
vasospastic infarctions were higher (63%) because we used some
‘enrichment’ strategies when selecting the patients for this analysis
that were shown to increase the rate of vasospasm and infarction
[36]. As our primary goal was to investigate the likelihood that
a localized sensor would pick up the vasospasm or infarction, we
used the criteria of ‘WFNS grade IV’, ‘Fisher grade 3’ [6], and
angiographically proven severe cerebral vasospasm. This selection
strategy is likely to explain the high rate of infarction in our study.
By placing the cerebral probe into the vessel territory of
corresponding ruptured aneurysm we observed, to some extent,
a reliable monitoring approach. This was particularly reliable for
MCA, ICA, and ACoA aneurysms. Concerning the ACA and
VBA aneurysms, the CVS location is inconsistent due to the
previously mentioned reasons. Despite the study limitations, we
believe that our results support the use of these methods for the
management of probe placement for specific aneurysm types.
Conclusions
The probability that a single focal probe will be situated in the
territory of severe CVS and infarction varies over a wide range.
More reliable CVS or infarction detection was observed in MCA
and ICA aneurysms compared to A1CA and VBA aneurysms. In
our opinion, focal ptiO2 or CBF or microdialysis measurements
are useful for MCA and ICA aneurysms, but may have a high (25–
50%) failure rate in patients with VBA and ACA aneurysms.
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